Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia

Inclusion Criteria: * Patients initially diagnosed with AML (excluding APL) according to WHO diagnostic criteria. * Patients who have not previously received other induction therapies (excluding hydroxyurea and leukapheresis). * Total white blood cell (WBC) count ≤ 25 × 10\^9/L. * Ages 18 to 60 years, inclusive, with no gender restrictions. * ECOG Performance Status score of 0-2. * Total bilirubin ≤ 3 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) ≤ 3 times ULN; Aspartate aminotransferase (AST) ≤ 3 times ULN; (excluding leukemia infiltration). * Endogenous creatinine clearance rate ≥ 30 ml/min. * Enrolled patients must be capable of understanding and willing to participate in the study, and must sign the informed consent form. Exclusion Criteria: * Patients with Acute Promyelocytic Leukemia (APL). * Patients with concomitant central nervous system leukemia or extramedullary leukemia involvement, such as testicular infiltration. * Patients with current or historical immunodeficiency virus infection. * Patients with active Hepatitis B or Hepatitis C infection. * Patients with a history of drug allergy, including but not limited to etoposide, azacitidine, venetoclax, daunorubicin, and cytarabine. * Patients with active or progressive malignant tumors or severe infections. * Patients with a left ventricular ejection fraction (LVEF) of less than 30%, classified as New York Heart Association (NYHA) Class III or above, and those deemed ineligible for enrollment by the investigator. * Patients who are pregnant or breastfeeding. * Patients who refuse to participate in the study.